Montelukast Sodium (MS), Polymeric Nanoparticles, Pulmonary Drug delivery, PLGA (poly lactic-co-glycolic acid)

Abstract

Pulmonary route as a targeted drug delivery system cuts the edge over other routes of administration in terms of local, site specific, patient friendly, and needle free drug delivery. Pulmonary route minimizes the systemic toxicity of drugs administered and facilitates accomplishment of optimal drug concentrations at the site of action in asthma and allied pulmonary disorders. Montelukast sodium (MS), a leukotriene receptor antagonist (LTRA) is used for the maintenance therapy of asthma & providing symptomatic relief from seasonal allergies. The objective of the present investigation was to formulate biodegradable polymeric nanoparticles (PNP) for controlled delivery of MS to broncho alveolar tract for management of asthma. To achieve the same, we have hypothesized to prepare drug loaded biodegradable and biocompatible nanoparticles using PLGA by solvent evaporation method which leads to long term site specific controlled release of the encapsulated drug over the treatment period in management of asthma. The prepared Montelukast sodium (MS) loaded PLGA nanoparticles were evaluated on the basis of particle size, zeta potential, % entrapment efficiency (%EE), Scanning Electron Microscopy analysis, In-vitro Drug release study.